Squarepoint
APRE icon

Squarepoint’s Aprea Therapeutics APRE Stock Holding History

Squarepoint’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-744
Closed -$43K – 2780
2021
Q4 		$43K Buy
+744
New +$65.7K ﹤0.01% 3041
2021
Q1 		– Sell
-1,309
Closed -$129K – 3079
2020
Q4 		$129K Buy
1,309
+840
+179% +$399K ﹤0.01% 2656
2020
Q3 		$225K Buy
+469
New +$262K ﹤0.01% 2010
2020
Q2 		– Sell
-408
Closed -$284K – 2208
2020
Q1 		$284K Buy
408
+37
+10% +$27.1K 0.01% 1319
2019
Q4 		$340K Buy
+371
New +$204K ﹤0.01% 1973

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Squarepoint's APRE Position: Q1 2022 in Review

Squarepoint sold out of Aprea Therapeutics (APRE) in Q1 2022, closing a stake of 744 shares — an estimated $43K sold.

Squarepoint first reported a position in APRE in Q4 2019 and held it in 5 quarters. The position peaked at $340K in Q4 2019. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

  • Squarepoint reported no remaining Aprea Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Squarepoint sold 744 Aprea Therapeutics shares in Q1 2022, an estimated $43K.
  • Squarepoint first reported a position in Aprea Therapeutics in Q4 2019 and held it in 5 quarters.
  • Squarepoint's Aprea Therapeutics position peaked at $340K in Q4 2019.
  • 40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.